CYTK — Cytokinetics Share Price
Last trade - 00:00- $7.48bn
- $7.49bn
- $7.53m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 993.82 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -68.76% | ||
| Return on Equity | n/a | ||
| Operating Margin | -6589.71% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 26.87 | 55.83 | 70.43 | 94.59 | 7.53 | 6.41 | 145.32 | -24.89% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.
Directors
- Robert Blum CEO (57)
- Ching Jaw CFO (58)
- David Cragg CHO (65)
- Andrew Callos EVP (52)
- Fady Malik EVP (56)
- Mark Schlossberg SVP (60)
- Muna Bhanji IND (58)
- Robert Califf IND (69)
- Santo Costa IND (75)
- John Henderson IND (76)
- Edward Kaye IND (72)
- B. Lynne Parshall IND (66)
- Sandford Smith IND (74)
- Wendell Wierenga IND (73)
- Nancy Wysenski IND (63)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 5th, 1997
- Public Since
- April 29th, 2004
- No. of Shareholders
- 45
- No. of Employees
- 423
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 104,576,087
- Address
- 350 Oyster Point Boulevard, SOUTH SAN FRANCISCO, 94080
- Web
- https://cytokinetics.com/
- Phone
- +1 6506243000
- Contact
- Diane Weiser
- Auditors
- Ernst & Young LLP
Latest News for CYTK
Upcoming Events for CYTK
Q1 2024 Cytokinetics Inc Earnings Release
Cytokinetics Inc Annual Shareholders Meeting
Cytokinetics Inc Annual Shareholders Meeting
Q2 2024 Cytokinetics Inc Earnings Release
Similar to CYTK
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 19:06 UTC, shares in Cytokinetics are trading at $71.56. This share price information is delayed by 15 minutes.
Shares in Cytokinetics last closed at $71.56 and the price had moved by +99.17% over the past 365 days. In terms of relative price strength the Cytokinetics share price has outperformed the S&P500 Index by +60.84% over the past year.
The overall consensus recommendation for Cytokinetics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Cytokinetics does not currently pay a dividend.
Cytokinetics does not currently pay a dividend.
Cytokinetics does not currently pay a dividend.
To buy shares in Cytokinetics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $71.56, shares in Cytokinetics had a market capitalisation of $7.48bn.
Here are the trading details for Cytokinetics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CYTK
Based on an overall assessment of its quality, value and momentum Cytokinetics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Cytokinetics is $95.06. That is 32.84% above the last closing price of $71.56.
Analysts covering Cytokinetics currently have a consensus Earnings Per Share (EPS) forecast of -$4.46 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cytokinetics. Over the past six months, its share price has outperformed the S&P500 Index by +78.57%.
As of the last closing price of $71.56, shares in Cytokinetics were trading +44.25% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cytokinetics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $71.56.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cytokinetics' management team is headed by:
- Robert Blum - CEO
- Ching Jaw - CFO
- David Cragg - CHO
- Andrew Callos - EVP
- Fady Malik - EVP
- Mark Schlossberg - SVP
- Muna Bhanji - IND
- Robert Califf - IND
- Santo Costa - IND
- John Henderson - IND
- Edward Kaye - IND
- B. Lynne Parshall - IND
- Sandford Smith - IND
- Wendell Wierenga - IND
- Nancy Wysenski - IND